Evidence map›Paper›PMID 38882479›Full record

ArticleRSC advances2024

Bioanalytical HPLC method with fluorescence detector for determination of Entresto™ when co-administered with ibuprofen and fexofenadine: a pharmacokinetic study.

Aya R Ahmed, Shereen M Galal, Mohamed A Korany, Manal A Elsheikh, Asser F Bedair, Marwa A A Ragab

Abstract read
In one paragraph

Article in RSC advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Aya R AhmedDepartment of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Alexandria University Alexandria Egypt ayarefaat1991@gmail.com +20 3 4871351 +20 3 5438851.ORCID https://orcid.org/0000-0001-8536-1507
Shereen M GalalDepartment of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Alexandria University Alexandria Egypt ayarefaat1991@gmail.com +20 3 4871351 +20 3 5438851.
Mohamed A KoranyDepartment of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Alexandria University Alexandria Egypt ayarefaat1991@gmail.com +20 3 4871351 +20 3 5438851.
Manal A ElsheikhDepartment of Pharmaceutics, Faculty of Pharmacy, Damanhour University Damanhour Egypt.
Asser F BedairDepartment of Pharmacology and Toxicology, Faculty of Pharmacy, Alexandria University Alexandria Egypt.ORCID https://orcid.org/0000-0001-6340-3745
Marwa A A RagabDepartment of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Alexandria University Alexandria Egypt ayarefaat1991@gmail.com +20 3 4871351 +20 3 5438851.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Entresto™ (LCZ696) has been approved globally for heart failure management. However, its lifelong use alongside over-the-counter (OTC) drugs like ibuprofen (IBU) and fexofenadine (FEX) necessitates an in-depth investigation of potential pharmacokinetic interactions, as they share the same metabolic and elimination pathways. This study aimed to develop a bioanalytical HPLC method with a fluorescence detector (FLD) to quantify LCZ696 analytes (valsartan, VAL; sacubitril, SAC; and sacubitril active metabolite, LBQ657) in rat plasma. Additionally, an

Identifiers

PMID38882479
PMCPMC11177748

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.